Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 31, 2021

Health Canada approves Tetra Covid-19 drug clinical trial application

Health Canada has provided positive feedback on Tetra Bio-Pharma’s clinical trial application to evaluate its drug candidate, ARDS-003, in Covid-19 patients.

Health Canada has provided positive feedback on Tetra Bio-Pharma’s clinical trial application to evaluate its drug candidate ARDS-003 in Covid-19 patients.

A new patent-protected therapeutic, ARDS-003 is developed for treating hyperinflammatory conditions, like those seen in Covid-19 patients.

The latest development comes after Health Canada concluded a full review of the animal toxicology and safety data to confirm that the new drug is safe for human use.

Tetra’s broad nonclinical data which includes genotoxicity, safety pharmacology and toxicities studies, evaluating the safety and pharmacokinetic profile of ARDS-003 meet the authority’s requirements for a New Molecular Entity, Health Canada Therapeutic Products Directorate, Office of Clinical Trials acknowledged.

The proposed study design, target population, and primary and secondary objectives as well as study’s endpoints in severe Covid-19 patients were approved by the authorities.

Tetra noted that this trial will be for the first-ever drug that uses an injectable sterile synthetic cannabinoid in Covid-19 patients.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The company will use this trial to show that its ARDS-003 could aid in preventing the acute respiratory distress linked to serious complications of Covid-19.

The randomised, double-blind, placebo-controlled trial will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ascending doses of ARDS-003 in hospitalised Covid-19 patients with pneumonia, who are at risk of developing acute respiratory distress syndrome.

Tetra Bio-Pharma CEO and CRO Dr Guy Chamberland said: “Getting the green light from the authorities to administer this trial in patients was the last missing step for Tetra to initiate ARDS-003 clinical development in Covid-19 patients.

“The preliminary approval of the study protocol, and prior review of the preclinical safety data, will allow us to move promptly through the Health Canada CTA revision process.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU